Research search

Reset all

287 matching records Analyze trends Open JSON Open API Download SQLite

Keyword search Author

Substances Psilocybin 3833 Psilocin 553

Date range quick select Last month Last year Last 5 years All time Custom range

BibTeX RIS CSV JSON SQLite

Executed search Sources: ClinicalTrials.gov 287 matching records are displayed.

Clear search

Latest Publications

Most recently published records currently stored in SQLite.

1-20

Last updated: Jul 2, 2026 22:01 UTC

Checking for newly published papers…

287 matching results

The Acute Effects of Psilocybin on Cognition, Memory, and Brain Function

This study will test the effects of psilocybin on memory and cognition in healthy participants using computerized tasks and magnetic resonance imaging (MRI). In a double-blind, placebo-controlled, repeated measures design in healthy participants, this study will test the effects of psilocybin on memory and cognition in healthy individuals using computerized ...

ClinicalTrials.gov 2026-06-14 Manoj Doss

ClinicalTrials.gov CLINICAL TRIAL psilocybin Brain ImagingAgingHealthy Volunteers Other HealthyPlacebo

Psilocybin-Assisted Psychotherapy for the Treatment of Severe Alcohol Use Disorder: A Double-Blind, Dose-Comparison Concurrent Control Randomized Trial

This study aims to determine the safety and preliminary efficacy of psilocybin-assisted psychotherapy in improving alcohol-related outcomes among adults with severe alcohol use disorder in a a double-blind, dose-comparison concurrent control, randomized trial. Participants will undergo structured psychotherapy and will be randomized to two psilocybin session...

ClinicalTrials.gov 2026-06-14 Brigham and Women's Hospital

ClinicalTrials.gov CLINICAL TRIAL psilocybin AnxietyAddictionBrain ImagingMechanism of ActionBiomarkersAgingEmotional ProcessingClinical TrialSafetyAdverse Events Clinical Trial Alcohol Use DisorderPsilocybin

Psilocybin as a Treatment for Chronic Pain in Smokers

The purpose of this study is to understand whether psilocybin therapy is safe and well tolerated in improving chronic pain and increasing motivation to quit smoking for people who have chronic pain and smoke cigarettes. Psilocybin is a psychedelic drug and the active ingredient in "magic mushrooms." Psilocybin is currently being studied in clinical trials bu...

ClinicalTrials.gov 2026-06-08 Yale University

ClinicalTrials.gov CLINICAL TRIAL psilocybin AddictionChronic PainHeadache / MigraineClinical TrialObservational StudySafety Clinical Trial Smokers With Chronic PainPsilocybin (drug)

PRISMatic: A Phase 1b Randomized, Double-Armed, Parallel-Group, Placebo-Controlled Trial of Psilocybin Efficacy With or Without Pimavanserin Pretreatment

Twenty healthy adults (≥21 years old) will be enrolled to evaluate the efficacy of a single oral dose of psilocybin (25 mg) administered with or without pretreatment using oral pimavanserin (34 mg) or placebo. Outcome assessments will occur at 1 week and 1 month following psilocybin administration. The purpose of this study is to clarify the receptor-level m...

ClinicalTrials.gov 2026-06-07 Johns Hopkins University

ClinicalTrials.gov CLINICAL TRIAL psilocybin Brain ImagingPharmacologyMechanism of ActionReceptor PharmacologyBiomarkersWellbeingClinical Trial Clinical Trial Mood (Psychological Function)Well Being

A Double Blind, Randomized Trial Investigating the Safety, Feasibility, and Mechanisms of Psychedelics in Healthy Older Adults With Low Well-being as Moderated by Biomarkers for Preclinical Alzheimer's Disease

This study is being conducted to understand changes in brain activity following administration of two different drugs (Psilocybin and Dextromethorphan) in older adults with low well-being. The main questions it aims to answer are, does psilocybin: 1. Acutely increase complexity of EEG activity in older adults with low well-being, as modulated by the presence...

ClinicalTrials.gov 2026-06-07 Jennifer Mitchell

ClinicalTrials.gov CLINICAL TRIAL psilocybin Brain ImagingMechanism of ActionBiomarkersAgingWellbeingAnimal StudyHealthy VolunteersOlder AdultsSafetyInflammation Clinical Trial Anhedonia in Healthy VolunteersOlder Adults (50-90 Years)

Multivariate Neural and Physiological Correlates of Psychedelic Sub-states: a Within-subjects, Healthy Volunteer Study With Experience-sampling

The main purpose of this study is to gain a better understanding of the distinct mental states and physical reactions that can arise during a psychedelic experience. By repeatedly assessing the same participants in an MRI while under the effects of psilocybin, the investigators want to identify reliable brain and body reactions arising during these psychedel...

ClinicalTrials.gov 2026-06-04 Robin Carhart-Harris, PhD, MA

ClinicalTrials.gov CLINICAL TRIAL psilocybin Brain ImagingAgingClinical TrialHealthy Volunteers Clinical Trial Psychedelic ExperiencesNeuroimaging

A Multi-site Randomized Controlled Trial of Psilocybin for Treatment-Resistant Depression (TRD) in Veterans

The purpose of this multi-site randomized controlled trial is to evaluate the efficacy and risks of psilocybin for the treatment of depression in U.S. military Veterans with and without (±) concurrent posttraumatic stress disorder. Treatment-resistant depression (TRD) is a serious mental health problem in Veterans, frequently comorbid with post-traumatic str...

ClinicalTrials.gov 2026-06-04 VA Office of Research and Development

ClinicalTrials.gov CLINICAL TRIAL psilocybin DepressionPTSDRandomized Controlled TrialTreatment-Resistant DepressionVeteransSafetyAdverse Events Randomized Controlled Trial Major DepressionPsilocybin

Effects of Repeated Dosing of Psilocybin on Obsessive-Compulsive Disorder: A Randomized, Waitlist-Controlled Study

This study aims to investigate the effects of repeated dosing of oral psilocybin on obsessive-compulsive disorder (OCD) symptomatology in a randomized, waitlist-controlled design with blinded independent ratings, and assess psychological mechanisms that may mediate psilocybin's therapeutic effects on OCD. Aim 1: To examine the effects of two doses of psilocy...

ClinicalTrials.gov 2026-06-03 Yale University

ClinicalTrials.gov CLINICAL TRIAL psilocybin OCDMechanism of Action Clinical Trial Obsessive-Compulsive DisorderPsilocybin

2 x 2 Factorial, Double-blind, Randomized Trial of 'Set and Setting': a Translational Study in Healthy Volunteers

One hundred twenty healthy participants, ages 21 to 70, who experience moderate-to-lower-than-average mental well-being will be evenly randomized into four different study arms, using a 2x2 factorial design. Depending on the study arm, participants will either receive an inactive placebo or up to 25mg psilocybin (oral dose), in one of two set and setting con...

ClinicalTrials.gov 2026-06-03 Robin Carhart-Harris, PhD, MA

ClinicalTrials.gov CLINICAL TRIAL psilocybin NeuroplasticityWellbeingEmotional ProcessingHealthy VolunteersDrug Interactions Clinical Trial Healthy Participants With Lower-than-average Mental Well-beingPsilocybin

The Role of the Subjective Experience in Supporting Positive Effects Following Psilocybin: a Randomized, Controlled Clinical Trial Using Risperidone in Healthy Adults

The purpose of this study is to determine the importance of the acute subjective experience induced by psilocybin (the primary component of "magic mushrooms") in facilitating positive outcomes. Participants in this study will be given psilocybin in combination with either a placebo or risperidone, an atypical antipsychotic that block the subjective effects o...

ClinicalTrials.gov 2026-06-01 University of Calgary

ClinicalTrials.gov CLINICAL TRIAL psilocybin AnxietyBiomarkersWellbeingPersonality ChangeClinical Trial Clinical Trial Investigating the Importance of the Subjective Psychedelic ExperiencePsilocybin high-dose

Imaging the Effects of Serotonin 2A Receptor Modulation on Synaptic Density in Treatment-resistant Depression (SYNVEST)

Limit: 5000 characters. Psilocybin, the chemical component of "magic mushrooms", has been administered with psychotherapy in several randomized clinical trials (RCTs) showing large and sustained antidepressant effects. In healthy volunteers, the psychedelic effects of psilocybin have been shown to be blocked by administration of certain medications such as r...

ClinicalTrials.gov 2026-05-31 Centre for Addiction and Mental Health

ClinicalTrials.gov CLINICAL TRIAL psilocybin DepressionNeuroplasticityBrain ImagingReceptor PharmacologyAgingClinical TrialRandomized Controlled TrialHealthy VolunteersTreatment-Resistant Depression Clinical Trial Treatment Resistant DepressionPsilocybin 25 mg

A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Psilocybin in Adults With Major Depressive Disorder (MDD)

Approximately 240 eligible adult participants (≥18 years old) who meet Diagnostic and Statistical Manual of Mental Disorders (DSM-5-TR) criteria for Major Depressive Disorder (MDD) will be enrolled. Participants will be randomly assigned to receive a single oral dose of Psilocybin 25 mg, Psilocybin 5 mg, or inactive placebo. The purpose of this study is to e...

ClinicalTrials.gov 2026-05-31 Usona Institute

ClinicalTrials.gov CLINICAL TRIAL psilocybin DepressionSafetyAdverse Events Clinical Trial Depressive DisorderMajor

Psilocybin: Capturing Brain Mechanisms of Motivation and Neurocognition in Individuals With Opioid Use Disorder

The goal of this study is to test addiction-related brain circuitry (motivation/reward and inhibition) as well as neurocognitive circuitry prior to and following low or high dose psilocybin (PEX010 from Filament). Using fMRI, we will examine brain circuits relevant to drug relapse as well as neurocognitive flexibility circuits in individuals with opioid use ...

ClinicalTrials.gov 2026-05-31 University of Pennsylvania

ClinicalTrials.gov CLINICAL TRIAL psilocybin AddictionBrain ImagingMechanism of Action Other Opioid Use DisorderPsilocybin (high dose)

A Phase 2a Study of Group Retreat Psilocybin Therapy for Cancer-Related Anxiety and Depression

This phase II trial tests the safety, side effects and how well group retreat psilocybin therapy works for the treatment of anxiety and depression in patients with solid tumors that have spread from where they first started (primary site) to other places in the body (metastatic) or with hematologic cancers for which no treatment is currently available (incur...

ClinicalTrials.gov 2026-05-28 University of Washington

ClinicalTrials.gov CLINICAL TRIAL psilocybin DepressionAnxietyClinical TrialObservational StudyCancer PatientsSafetyAdverse Events Clinical Trial AnxietyDepression

Targeting Reward Circuits: Psilocybin as a Novel Therapy for Residual Anhedonia

The primary objective is to evaluate whether a single dose of psilocybin (25 mg), compared to placebo, can restore fronto-striatal reward circuit function and thereby improve anhedonia and emotional blunting in individuals with residual symptoms despite ongoing SSRI or SNRI treatment. This will be assessed using precision functional mapping (PFM), task-based...

ClinicalTrials.gov 2026-05-26 NYU Langone Health

ClinicalTrials.gov CLINICAL TRIAL psilocybin Brain ImagingEmotional Processing Other AnhedoniaEmotional Blunting

The Safety and Acceptability of Psilocybin With Support and With Massed Prolonged Exposure Therapy for PTSD

This pilot study will examine the safety, tolerability, acceptability, and efficacy of combination psilocybin + psychotherapy to decrease PTSD symptoms. Participants will be randomized into two different treatment groups, allowing the investigators to directly compare PE augmented with psilocybin and psilocybin-assisted psychotherapy. The Primary objective i...

ClinicalTrials.gov 2026-05-25 Emory University

ClinicalTrials.gov CLINICAL TRIAL psilocybin DepressionPTSDSafetyAdverse Events Clinical Trial PTSDpsilocybin

Effects of Psilocybin With Psychological Support on Anhedonia in Treatment-resistant Depression: a Randomized Controlled Pilot Trial

The purpose of this study is to evaluate the efficacy of psilocybin on the symptom of anhedonia in individuals with treatment-resistant major depressive disorder.

ClinicalTrials.gov 2026-05-21 University of Colorado, Denver

ClinicalTrials.gov CLINICAL TRIAL psilocybin DepressionRandomized Controlled TrialTreatment-Resistant Depression Randomized Controlled Trial Major Depressive DisorderAnhedonia

Group Psilocybin-Assisted Therapy for Post-Traumatic Stress Disorder

This study is a community-informed, pragmatic, open-label, phase 1 clinical trial of group-format psilocybin-assisted therapy (GPAT) for individuals with post-traumatic stress disorder (PTSD). The primary objectives of this phase 1 study are to assess the safety and feasibility of (GPAT) for individuals with (PTSD) and to evaluate preliminary effects on PTSD...

ClinicalTrials.gov 2026-05-21 University of New Mexico

ClinicalTrials.gov CLINICAL TRIAL psilocybin PTSDClinical TrialHealthcare WorkersSafetyAdverse Events Clinical Trial PTSDPsilocybin

A Pilot Mechanistic Study of Psilocybin-Assisted Therapy as a Treatment for Depression

Depression is the leading cause of disability worldwide, affecting an estimated 300 million people. Despite available treatments, response rates remain modest, and treatment resistance is common. Novel treatments are needed that act rapidly, produce lasting effects and work differently than existing antidepressants. In clinical trials, psilocybin has shown p...

ClinicalTrials.gov 2026-05-19 Washington University School of Medicine

ClinicalTrials.gov CLINICAL TRIAL psilocybin DepressionBiomarkersPsychological FlexibilityClinical Trial Clinical Trial DepressionPsilocybin (Usona Institute)

Psilocybin-assisted Cognitive Behavioral Therapy for Depression

The primary objectives of this clinical investigation are to (1) determine the acceptability and feasibility of joining psilocybin-assisted therapy with cognitive-behavioral therapy (PA-CBT) for patients with depression, (2) optimize CBT to most effectively integrate the psilocybin experience with psychotherapy and (3) examine the clinical benefit of psilocy...

ClinicalTrials.gov 2026-05-18 University of California, Los Angeles

ClinicalTrials.gov CLINICAL TRIAL psilocybin Depression Other Major Depressive DisorderPsilocybin

Email alerts Open a focused sheet to subscribe broadly or narrow notifications by keyword, author, journal, topic, substance, and cited DOI.

Analytics Open a focused analytics workspace for timeline ranges, publication trends, top journals, topics, and authors.

Source	Count	Share	Status
Europe PMC	2,553	64.2%	Active
PubMed	302	7.6%	Active
ClinicalTrials.gov	287	7.2%	Active
OpenAlex	283	7.1%	Active
PsyArXiv	216	5.4%	Active
Crossref	157	4%	Active
bioRxiv	142	3.6%	Active

Psilocybin Research Publication Tracker

Research search

Latest Publications